1. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement.
JAMA 2016;316:1997–2007.
2. Bibbins-Domingo K; U.S. Preventive Services Task Force. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement.
Ann Intern Med 2016;164:836–845.
3. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation 2019;140:e596–e646.
4. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.
JAMA 2001;286:180–187.
5. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol 2014;63(25 Pt B):2935–2959.
6. Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk.
Ann Intern Med 2018;169:20–29.
7. Jung HH. Statin use and outcome risks according to predicted CVD risk in Korea: a retrospective cohort study.
PLoS One 2021;16:e0245609.
8. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet 2019;393:31–39.
9. Neuen BL, Young T, Heerspink HJ, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Lancet Diabetes Endocrinol 2019;7:845–854.
10. Chun KJ, Jung HH. SGLT2 inhibitors and kidney and cardiac outcomes according to estimated GFR and albuminuria levels: a meta-analysis of randomized controlled trials.
Kidney Med 2021;3:732–744.
11. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N Engl J Med 2014;371:993–1004.
12. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.
N Engl J Med 2020;383:2219–2229.
13. Haller H, Bertram A, Stahl K, Menne J. Finerenone: a new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD?
Curr Hypertens Rep 2016;18:41.
14. Jung HH. On-treatment blood pressure and long-term outcomes in chronic kidney disease. Nephrol Dial Transplan 2022;37:1088–1098.
15. Seong SC, Kim YY, Khang YH, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea.
Int J Epidemiol 2017;46:799–800.
16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate.
Ann Intern Med 2009;150:604–612.
17. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.
Ann Intern Med 2013;158:825–830.
18. Uno H, Cai T, Pencina MJ, D’Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.
Stat Med 2011;30:1105–1117.
19. Anker SD, Butler J, Filippatos G, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial.
Circulation 2021;143:337–349.
20. Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes Endocrinol 2021;9:22–31.
21. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet 2010;376:1670–1681.
22. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2016;316:2008–2024.
23. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease.
Kidney Int 2020;98(4S):S1–S115.
24. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020.
Diabetes Care 2020;43(Suppl 1):S98–S110.
26. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.
N Engl J Med 2019;381:1609–1620.
27. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes.
N Engl J Med 2021;385:2252–2263.
28. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.
Lancet Diabetes Endocrinol 2015;3:514–525.
29. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure.
JAMA 2011;305:1553–1559.
30. Tangri N, Grams ME, Levey AS, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis.
JAMA 2016;315:164–174.
31. Grams ME, Sang Y, Ballew SH, et al. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.
Kidney Int 2018;93:1442–1451.
32. Ramspek CL, Evans M, Wanner C, et al. Kidney failure prediction models: a comprehensive external validation study in patients with advanced CKD.
J Am Soc Nephrol 2021;32:1174–1186.
33. Sumida K, Nadkarni GN, Grams ME, et al. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis : an individual participant-based meta-analysis.
Ann Intern Med 2020;173:426–435.
34. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications.
J Am Soc Nephrol 2011;22:147–155.